Every 10-Q that Revolution Medicines, Inc. (RVMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RVMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVMD filings page.
Revolution Medicines, a late-stage oncology company focused on RAS-addicted cancers, reported sharply higher spending and losses for the quarter and six months ended June 30, 2026. Research and development expense was $394,919 (in thousands) for the quarter versus $224,134 (in thousands) a year earlier, while general and administrative expense rose to $110,213 (in thousands) from $40,580 (in thousands). Quarterly net loss widened to $644,371 (in thousands), including a $151,031 (in thousands) non-cash loss from the change in fair value of warrant liabilities.
For the first half of 2026, net loss reached $1,098,187 (in thousands). To fund its expanding clinical pipeline, the company raised substantial capital, including a follow-on equity offering of 12,147,887 shares at $142.00 per share for net proceeds of approximately $1,651,354 (in thousands), at-the-market sales, $500,000 (in thousands) from two tranches of a Royalty Purchase Agreement, and $500,000 (in thousands) of 0.50% convertible senior notes due 2033. At June 30, 2026, cash and cash equivalents were $815,435 (in thousands) and marketable securities were $3,122,534 (in thousands), with total assets of $4,323,270 (in thousands). Management states that this cash, cash equivalents and marketable securities will fund planned operations for at least 12 months.
Revolution Medicines reported a larger net loss for the quarter ended March 31, 2026 as it sharply increased investment in late-stage oncology programs. Net loss was $453.8 million, compared with $213.4 million a year earlier, driven mainly by higher research and development and stock-based compensation expenses.
Research and development spending rose to $344.0 million, while general and administrative costs reached $101.3 million. The company held $1.91 billion in cash, cash equivalents and marketable securities and believes this will fund operations for at least 12 months. It also expanded financing capacity through at-the-market equity programs, a royalty funding agreement with Royalty Pharma, and, after quarter-end, large common stock and convertible notes offerings.
Revolution Medicines (RVMD) reported a larger quarterly loss as it accelerates development of its RAS(ON) therapies. For the quarter ended September 30, 2025, net loss was $305.2 million or $1.61 per share, compared with $156.3 million a year ago. Operating expenses rose to $315.3 million, driven by research and development of $262.5 million and general and administrative of $52.8 million.
Liquidity remains strong with $217.4 million in cash and equivalents and $1.714 billion in marketable securities (total $1.93 billion) as of September 30, 2025, and management believes existing resources will fund operations for at least 12 months. RVMD entered a $250.0 million revenue participation agreement with Royalty Pharma, recorded as a liability of $256.5 million, with tiered royalty rates of 2.55% up to $2.0 billion in annual sales, 1.50% between $2.0–$4.0 billion, and 0.60% between $4.0–$8.0 billion. The company also established a senior secured term loan facility of up to $750.0 million, contingent on future regulatory and commercial milestones, with no amounts drawn. Shares outstanding were 189,710,951 as of September 30, 2025.